Abstract:Objective:To establish 6 subclones of gefitinib-resistant cells from gefitinib-sensitive lung adenocarcinoma cell line PC9 and study their biological characteristics.Methods:The PC9 cells were induced to mutate by a mutagen MNNG and selected.The subclone of gefitinib-resistant cell was obtained by limited dilution.The sensitivity and IC50 for gefitinib of various cell lines were determined by MTT assay.The different profile of gene expression between the wildtype PC9 cell and the gefitinib-resistant cells were determined by DNA microarray.Fibronectin and collagen Ⅳ expressions in various PC9 cell lines were checked by immunohistochemistry.Cell cycle was analyzed by flow cytometry.Results:Two resistant cell lines to gefitinib were obtained,named PC9/G2 and PC9/G4,respectively,and the IC50 for the gefitinib was 7-10 μmol/L,about 160 to 260 folds higher compared with wildtype PC9(IC50:0.03-0.05 μmol/L).The doubling time of PC9 cells and PC9/G2 cells were(16.2±3.5)h and(36.5±4.8)h,respectively.The gene expression profile had significant difference between wildtype PC9 cells and resistant PC9/G2 cells.Gene function annotation and grouping showed that in PC9/G2 cells fatty acid metabolism-and oxidative phosphorylation-related genes were down-regulated,while glycolysis-genes were up-regulated;the expressions of ribosomal subproteins were down-regulated,and the gene groups located in Golgi Stack,cisternae,clathrin-coated vesicle were up-regulated;the protein-secreting function was enhanced and ubiquitin-proteosome system was activated;DNA repair and helicase genes were also up-regulated.For the genes with protein kinase activity,30 of them were up-regulated,while 11 of them were down-regulated;15 genes with phosphoprotein phosphatase activity were up-regulated.For the genes with GTP binding function,21 of them were up-regulated,while 4 of them were down-regulated;8 genes related to cytoskeletal movement and cell adhesion were up-regulated;integrin beta1 subunit,insulin-like receptor and positive regulative factors for NFκB cascade were up-regulated.Conclusion:Six lines of gefitinib-resistant PC9 cells were successfully established.Our results suggested that moderate resistance to gefitinid might be related with extracellular matrix changes and adhesion signaling cascade,while high resistance may be due to activation of instead signaling pathway and the downstream molecules of signaling pathway.

Integrin Β1 Participates in Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

Integrin Β1-Mediated Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Occurs Via the Phosphoinositide 3-Kinase-dependent Pathway.

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Drug Resistance Mechanism of Non Small Cell Lung Cancer PC9/AB2 Cell Line with Acquired Drug Resistance to Gefitinib

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

Role of Insulin-Like Growth Factor 1 in Drug Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer

Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.

[Sensitivity of Two Cell Lines with Acquired Resistance to Gefitinib to Several Chemotherapeutic Drugs].

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Data from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin Β3 Signaling in EGFR-Mutant Lung Cancer

Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells

BIM Induction of Apoptosis Triggered by EGFR-sensitive and Resistance Cell Lines of Non-Small-cell Lung Cancer

Effect of Wnt Signaling Suppression on Gefitinib in Non Small Cell Lung Cancer Cell Lines

Acquired resistance to EGFR TKIs mediated by TGF-beta1/integrin beta3 signaling in EGFR-mutant lung cancer.

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells

Selection and establishment of gefitinib-resistant PC9 cell line and its gene expression profile

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Blocking the PI3K/AKT and MEK/ERK Signaling Pathways Can Overcome Gefitinib-resistance in Non-Small Cell Lung Cancer Cell Lines